cefotetan (cefotan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. It is FDA approved for the treatment of urinary tract infection, lower respiratory tract infection, skin and skin structure infections, gynecologic infection, intra-abdominal infection, and bone and joint infection; and for prophylaxis of postoperative infection. The bactericidal action of cefotetan results from inhibition of cell wall synthesis. The methoxy group in the 7-alpha position provides cefotetan with a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinase of gram-negative bacteria. Common adverse reactions include diarrhea and nausea. As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels.   NCATS

Chemistry

  • SMILES: CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
  • InChIKey: SRZNHPXWXCNNDU-IXOPCIAXSA-N
  • Mol. Mass: 575.63
  • ALogP: -1.4
  • ChEMBL Molecules:
    cefotetan  
    cefotetan disodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0010 - $32.8550
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid | apacef | cefotan | cefotetan | cefotetan disodium | cefotetan sodium | cefotetanum | ici-156834 | yamatetan | ym-09330

Organizations (10)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (7)


 

Bone Diseases, Infectious (approved 1985)

Infections

Intraabdominal Infections (approved 1985)

Reproductive Tract Infections (approved 1985)

Respiratory Tract Infections (approved 1985)

Skin Diseases, Bacterial (approved 1985)

Urinary Tract Infections (approved 1985)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Cholecystitis (Phase 1)

Colorectal Surgery (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue